+关注
Yue7
Yue Shunxiang
IP属地：未知
8
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Yue7
2021-12-24
Cool
U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19
Yue7
2021-12-24
Cool
抱歉，原内容已删除
Yue7
2021-12-24
Go9oooooood
抱歉，原内容已删除
Yue7
2021-12-24
Cool
抱歉，原内容已删除
Yue7
2021-12-16
Good
@46d9935c:2021年迄今录得机构净流入最高的20只股票回报率为32%
Yue7
2021-11-01
Share
@小虎活动:[Halloween Game] Trade or Treat!
Yue7
2021-11-01
Share
@小虎活动:[Halloween Game] Trade or Treat!
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3562111968746343,"uuid":"3562111968746343","gmtCreate":1599018283888,"gmtModify":1610159468522,"name":"Yue7","pinyin":"yue7","introduction":"","introductionEn":"","signature":"Yue Shunxiang","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":29,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.13%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":698952783,"gmtCreate":1640286687678,"gmtModify":1640286687754,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698952783","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p>\n<p>The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p>\n<p>As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p>\n<p>The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p>\n<p>Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p>\n<p>The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p>\n<p>The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p>\n<p>Some experts question whether there will be much of a role for the Merck drug in the U.S.</p>\n<p>“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p>\n<p>For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p>\n<p>The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p>\n<p>Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p>\n<p>The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p>\n<p>Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:31 GMT+8 <a href=https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/><strong>SeattleTimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug ...</p>\n\n<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRK":"默沙东"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952511,"gmtCreate":1640286571653,"gmtModify":1640286571653,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go9oooooood","listText":"Go9oooooood","text":"Go9oooooood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952511","repostId":"1152565085","repostType":4,"repost":{"id":"1152565085","pubTimestamp":1640272176,"share":"https://www.laohu8.com/m/news/1152565085?lang=&edition=full","pubTime":"2021-12-23 23:09","market":"us","language":"en","title":"Intel to Expand in France, Germany and Italy in Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1152565085","media":"Bloomberg","summary":"(Bloomberg) -- Intel Corp.’s global push to increase capacity will include adding facilities in Fran","content":"<p>(Bloomberg) -- Intel Corp.’s global push to increase capacity will include adding facilities in France and Italy, as well as putting a major production site in Germany, according to people familiar with negotiations.</p>\n<p>France will be home to a research and design center, and Italy will be the location of a test and assembly factory, according to the people, who asked not to be identified because the plan hasn’t been announced. The main wafer fabrication plant, or fab, will likely be built in Germany, according to the people. Altogether, the expansion will cost tens of billions of dollars.</p>\n<p>Chief Executive Officer Pat Gelsinger is trying to restore the world’s largest chipmaker to its former glory. The company has lost its technological edge to rivals and ceded market share -- something the spending binge is meant to address. Gelsinger also wants to bring more production back to the U.S. and Europe, counterbalancing Asia’s manufacturing dominance.</p>\n<p>Representatives of the French, German and Italian governments declined to comment, as did Intel spokespeople in Europe and the U.S.</p>\n<p>For Europe, the move would slow its decline as a manufacturing base in the $400 billion chip industry. The U.S. company has an existing plant in Ireland and there are older former Advanced Micro Devices Inc. processor factories that are owned by Globalfoundries Inc. in Dresden, Germany. But European manufacturers typically don’t make the kind of advanced logic chips that are regarded as the state of the art in the industry.</p>\n<p>NXP Semiconductors NV and STMicroelectronics NV are the continent’s two largest homegrown chipmakers. They focus on parts for cars and other equipment -- rather than the advanced computer processors that are Intel’s specialty.</p>\n<p>A global chip shortage also has renewed concerns about the concentration of production in Asia. Manufacturers such as Taiwan Semiconductor Manufacturing Co. and South Korea’s Samsung Electronics Co. have grown increasingly deft at producing chips, forcing Intel to play catch-up. Gelsinger has argued that spreading manufacturing around the world will help avoid the kinds of supply constraints that have hobbled whole industries this year, including automakers.</p>\n<p>Part of Gelsinger’s plan is to build factories that make chips for other companies, directly rivaling TSMC in the so-called foundry business. Until now, Intel has typically only manufactured chips of its own design.</p>\n<p>To help fund his ambitions, he’s called on lawmakers on both sides of the Atlantic to give public money in the form of tax breaks and grants to chipmakers willing to build plants in Europe and the U.S.</p>\n<p>By spreading around Intel’s spending, Gelsinger may be trying to placate as many EU members as he can to try to make sure that none of them try to object any central funding that’s made available. But the plans aren’t final yet. The mega-fab will likely be built in Saxony, with German regions of Saxony-Anhalt and Bavaria also in the running for the new factory.</p>\n<p>Intel’s ambitious new ventures could bring thousands of jobs. The company is also planning to create 4,000 jobs in Malaysia via a $7.1 billion investment in new chip packaging facilities.</p>\n<p>Intel’s shares increased 1.2% in early trading Thursday.</p>\n<p>Even with the potential government help, Intel is budgeting as much as $28 billion for new plants and equipment in 2022, up from roughly $18 billion this year. The spending plans have jarred investors, who worry about the toll on profit. But the massive increase in expenditures will only put Intel on course to keep up with TSMC and Samsung’s spending.</p>\n<p>Shares of Intel, based in Santa Clara, California, have gained just 2.3% this year -- even as its peers have enjoyed boom times. The Philadelphia Stock Exchange Semiconductor Index has climbed 39%, with companies such as Nvidia Corp. more than doubling.</p>\n<p>State-of-the art chip production plants cost more than $20 billion, and their most expensive component -- machinery -- is usually obsolete within five years. The German plant could have a price tag in that range. The Italian test and assembly plant, meanwhile, will cost around $10 billion. Intel and government officials there are still negotiating on the site, with Sicily being one area under consideration, according to one of the people familiar with the situation.</p>\n<p>The French R&D center may be built in either Paris or Grenoble, according to another person. Such facilities typically cost only a fraction of the amount needed to build a factory.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel to Expand in France, Germany and Italy in Comeback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel to Expand in France, Germany and Italy in Comeback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 23:09 GMT+8 <a href=https://finance.yahoo.com/news/intel-expand-france-germany-italy-091904071.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Intel Corp.’s global push to increase capacity will include adding facilities in France and Italy, as well as putting a major production site in Germany, according to people familiar ...</p>\n\n<a href=\"https://finance.yahoo.com/news/intel-expand-france-germany-italy-091904071.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://finance.yahoo.com/news/intel-expand-france-germany-italy-091904071.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152565085","content_text":"(Bloomberg) -- Intel Corp.’s global push to increase capacity will include adding facilities in France and Italy, as well as putting a major production site in Germany, according to people familiar with negotiations.\nFrance will be home to a research and design center, and Italy will be the location of a test and assembly factory, according to the people, who asked not to be identified because the plan hasn’t been announced. The main wafer fabrication plant, or fab, will likely be built in Germany, according to the people. Altogether, the expansion will cost tens of billions of dollars.\nChief Executive Officer Pat Gelsinger is trying to restore the world’s largest chipmaker to its former glory. The company has lost its technological edge to rivals and ceded market share -- something the spending binge is meant to address. Gelsinger also wants to bring more production back to the U.S. and Europe, counterbalancing Asia’s manufacturing dominance.\nRepresentatives of the French, German and Italian governments declined to comment, as did Intel spokespeople in Europe and the U.S.\nFor Europe, the move would slow its decline as a manufacturing base in the $400 billion chip industry. The U.S. company has an existing plant in Ireland and there are older former Advanced Micro Devices Inc. processor factories that are owned by Globalfoundries Inc. in Dresden, Germany. But European manufacturers typically don’t make the kind of advanced logic chips that are regarded as the state of the art in the industry.\nNXP Semiconductors NV and STMicroelectronics NV are the continent’s two largest homegrown chipmakers. They focus on parts for cars and other equipment -- rather than the advanced computer processors that are Intel’s specialty.\nA global chip shortage also has renewed concerns about the concentration of production in Asia. Manufacturers such as Taiwan Semiconductor Manufacturing Co. and South Korea’s Samsung Electronics Co. have grown increasingly deft at producing chips, forcing Intel to play catch-up. Gelsinger has argued that spreading manufacturing around the world will help avoid the kinds of supply constraints that have hobbled whole industries this year, including automakers.\nPart of Gelsinger’s plan is to build factories that make chips for other companies, directly rivaling TSMC in the so-called foundry business. Until now, Intel has typically only manufactured chips of its own design.\nTo help fund his ambitions, he’s called on lawmakers on both sides of the Atlantic to give public money in the form of tax breaks and grants to chipmakers willing to build plants in Europe and the U.S.\nBy spreading around Intel’s spending, Gelsinger may be trying to placate as many EU members as he can to try to make sure that none of them try to object any central funding that’s made available. But the plans aren’t final yet. The mega-fab will likely be built in Saxony, with German regions of Saxony-Anhalt and Bavaria also in the running for the new factory.\nIntel’s ambitious new ventures could bring thousands of jobs. The company is also planning to create 4,000 jobs in Malaysia via a $7.1 billion investment in new chip packaging facilities.\nIntel’s shares increased 1.2% in early trading Thursday.\nEven with the potential government help, Intel is budgeting as much as $28 billion for new plants and equipment in 2022, up from roughly $18 billion this year. The spending plans have jarred investors, who worry about the toll on profit. But the massive increase in expenditures will only put Intel on course to keep up with TSMC and Samsung’s spending.\nShares of Intel, based in Santa Clara, California, have gained just 2.3% this year -- even as its peers have enjoyed boom times. The Philadelphia Stock Exchange Semiconductor Index has climbed 39%, with companies such as Nvidia Corp. more than doubling.\nState-of-the art chip production plants cost more than $20 billion, and their most expensive component -- machinery -- is usually obsolete within five years. The German plant could have a price tag in that range. The Italian test and assembly plant, meanwhile, will cost around $10 billion. Intel and government officials there are still negotiating on the site, with Sicily being one area under consideration, according to one of the people familiar with the situation.\nThe French R&D center may be built in either Paris or Grenoble, according to another person. Such facilities typically cost only a fraction of the amount needed to build a factory.","news_type":1},"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952698,"gmtCreate":1640286479224,"gmtModify":1640286479327,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952698","repostId":"1122468807","repostType":4,"repost":{"id":"1122468807","pubTimestamp":1640268939,"share":"https://www.laohu8.com/m/news/1122468807?lang=&edition=full","pubTime":"2021-12-23 22:15","market":"us","language":"en","title":"Zynex acquires Kestrel Labs for $31M","url":"https://stock-news.laohu8.com/highlight/detail?id=1122468807","media":"seekingalpha","summary":"Zynex(NASDAQ:ZYXI)has acquired 100% of Kestrel Labs, a laser-based, noninvasive patient monitoring t","content":"<p>Zynex(NASDAQ:ZYXI)has acquired 100% of Kestrel Labs, a laser-based, noninvasive patient monitoring technology company.</p>\n<p>The transaction closed on December 22, 2021 at an approx. value of $31M, consisting of $16M in cash and ~$15M in Zynex common stock.</p>\n<p>ZYXI shares down 1.4% premarket at $10.42.</p>\n<p>Kestrel Labs' proprietary NiCO CO-Oximeter laser-based photoplethysmography patient monitoring technology identifies, measures, and monitors four crucial species of hemoglobin, which include O2Hb (oxygenated hemoglobin), RHb (reduced hemoglobin), COHb (carboxyhemoglobin), and metHb (methemoglobin).</p>\n<p>\"We will begin integrating Kestrel Labs' two main products into our existing monitoring portfolio and seek regulatory clearance,\" said Thomas Sandgaard, Founder, Chairman, and CEO of Zynex.</p>\n<p>Kestrel Labs' laser-based technology allows it to measure distinct parameters, including distinguishing between hemoglobin bound to carbon monoxide rather than to oxygen, which would lead to better quality of care.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zynex acquires Kestrel Labs for $31M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZynex acquires Kestrel Labs for $31M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:15 GMT+8 <a href=https://seekingalpha.com/news/3783027-zynex-acquires-kestrel-labs-for-31m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zynex(NASDAQ:ZYXI)has acquired 100% of Kestrel Labs, a laser-based, noninvasive patient monitoring technology company.\nThe transaction closed on December 22, 2021 at an approx. value of $31M, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3783027-zynex-acquires-kestrel-labs-for-31m\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZYXI":"Zynex, Inc."},"source_url":"https://seekingalpha.com/news/3783027-zynex-acquires-kestrel-labs-for-31m","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1122468807","content_text":"Zynex(NASDAQ:ZYXI)has acquired 100% of Kestrel Labs, a laser-based, noninvasive patient monitoring technology company.\nThe transaction closed on December 22, 2021 at an approx. value of $31M, consisting of $16M in cash and ~$15M in Zynex common stock.\nZYXI shares down 1.4% premarket at $10.42.\nKestrel Labs' proprietary NiCO CO-Oximeter laser-based photoplethysmography patient monitoring technology identifies, measures, and monitors four crucial species of hemoglobin, which include O2Hb (oxygenated hemoglobin), RHb (reduced hemoglobin), COHb (carboxyhemoglobin), and metHb (methemoglobin).\n\"We will begin integrating Kestrel Labs' two main products into our existing monitoring portfolio and seek regulatory clearance,\" said Thomas Sandgaard, Founder, Chairman, and CEO of Zynex.\nKestrel Labs' laser-based technology allows it to measure distinct parameters, including distinguishing between hemoglobin bound to carbon monoxide rather than to oxygen, which would lead to better quality of care.","news_type":1},"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952835,"gmtCreate":1640286465896,"gmtModify":1640286465896,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952835","repostId":"1199712599","repostType":4,"repost":{"id":"1199712599","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640269826,"share":"https://www.laohu8.com/m/news/1199712599?lang=&edition=full","pubTime":"2021-12-23 22:30","market":"us","language":"en","title":"Stocks rise for a third day from omicron scare, Dow rises 100 points","url":"https://stock-news.laohu8.com/highlight/detail?id=1199712599","media":"Tiger Newspress","summary":"All three major averages were up Thursday morning, building on back-to-back sessions of gains as fea","content":"<p>All three major averages were up Thursday morning, building on back-to-back sessions of gains as fears the Omicron variant would derail economic growth cooled among investors who sold-off risky assets at the start of the week on reports of swelling case numbers.</p>\n<p>The Nasdaq briefly jumped 180 points, while the Dow Industrial Average and S&P 500 also edged higher.</p>\n<p>Investors are weighing a trove of economic releases this morning. The Labor Department reported that initial jobless claims totaled 205,000, sustaining a downward trend from the highs of their pandemic peak and reflecting labor market tightness brought on by a demand for workers heading into the new year. The latest print brings the four-week moving average for new claims to its lowest in 52 years, ticking up by 2,750 week-over-week to reach 206,250.</p>\n<p>U.S. durable goods orders rose by 2.5% in November, up from the prior month, boosted by a sharp rise in aircraft orders.</p>\n<p>Meanwhile, U.S. consumer prices accelerated at the fastest pace in nearly four decades as shoppers confront rising inflation levels ahead of the holidays.</p>\n<p>In Wednesday's trading session, investors weighed an upbeat print on consumer confidence levels and the release of an upwardly revised estimate for domestic GDP, placing all three major averages in the green after a mixed open.</p>\n<p>The Conference Board reported consumer confidence increased by a greater-than-expected margin in December,with the headline index at 115.8 during the month and higher than Bloomberg’s consensus estimates of 111.0. In November, the index had a reading of 111.9, revised from an initial report of 109.5. Meanwhile, the nation’s gross domestic product grew at an annual rate of 2.3% in the third quarter in the final estimate from the Bureau of Economic Analysis after the initial report of 2.1%.</p>\n<p>“We’ve been saying that this is definitely a buy the dip sort of market because we expect more earnings upgrades to come,” Anik Sen, PineBridge Investments global head of equities told Yahoo Finance Live. “We think that the real debate should be about the length and strength of the economic cycle ahead.”</p>\n<p>The clock is also ticking on ayear-end Santa Claus Rally— one in which stocks climb higher in the final seven trading sessions of a year, plus the first two trading days of the new year. Starting tomorrow, traders will see whether 92 years of data uphold.</p>\n<p>For reasons unclear, over the past 92 years, the S&P 500 gained 77% of the time during the year-end rally period, according to data from Sundial Capital Research. The average gain in this nine-day trading period tallied 2.66%.</p>\n<p>Separately, Oppenheimer chief investment strategistJohn Stoltzfusdisclosedthe most bullish price target on the S&P 500, forecasting a 14% climb to 5,330 by the end of 2022. The 38-year Wall Street veteran’s estimate beats even the most optimistic of his peers, BMO Capital Markets’s Brian Belski, who projected S&P 500 5,300.</p>\n<p>Meanwile, Pfizer (PFE)received authorization from the U.S. Food and Drug Administration for its at-home COVID-19 pill following clinical trial data that showed the treatment was 90% effective at preventing hospitalizations and deaths in high-risk patients. Shares of Pfizer gained more than 2% in Wednesday's session following the news and closed up 1.02% at $59.55 a piece.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks rise for a third day from omicron scare, Dow rises 100 points</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks rise for a third day from omicron scare, Dow rises 100 points\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-23 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>All three major averages were up Thursday morning, building on back-to-back sessions of gains as fears the Omicron variant would derail economic growth cooled among investors who sold-off risky assets at the start of the week on reports of swelling case numbers.</p>\n<p>The Nasdaq briefly jumped 180 points, while the Dow Industrial Average and S&P 500 also edged higher.</p>\n<p>Investors are weighing a trove of economic releases this morning. The Labor Department reported that initial jobless claims totaled 205,000, sustaining a downward trend from the highs of their pandemic peak and reflecting labor market tightness brought on by a demand for workers heading into the new year. The latest print brings the four-week moving average for new claims to its lowest in 52 years, ticking up by 2,750 week-over-week to reach 206,250.</p>\n<p>U.S. durable goods orders rose by 2.5% in November, up from the prior month, boosted by a sharp rise in aircraft orders.</p>\n<p>Meanwhile, U.S. consumer prices accelerated at the fastest pace in nearly four decades as shoppers confront rising inflation levels ahead of the holidays.</p>\n<p>In Wednesday's trading session, investors weighed an upbeat print on consumer confidence levels and the release of an upwardly revised estimate for domestic GDP, placing all three major averages in the green after a mixed open.</p>\n<p>The Conference Board reported consumer confidence increased by a greater-than-expected margin in December,with the headline index at 115.8 during the month and higher than Bloomberg’s consensus estimates of 111.0. In November, the index had a reading of 111.9, revised from an initial report of 109.5. Meanwhile, the nation’s gross domestic product grew at an annual rate of 2.3% in the third quarter in the final estimate from the Bureau of Economic Analysis after the initial report of 2.1%.</p>\n<p>“We’ve been saying that this is definitely a buy the dip sort of market because we expect more earnings upgrades to come,” Anik Sen, PineBridge Investments global head of equities told Yahoo Finance Live. “We think that the real debate should be about the length and strength of the economic cycle ahead.”</p>\n<p>The clock is also ticking on ayear-end Santa Claus Rally— one in which stocks climb higher in the final seven trading sessions of a year, plus the first two trading days of the new year. Starting tomorrow, traders will see whether 92 years of data uphold.</p>\n<p>For reasons unclear, over the past 92 years, the S&P 500 gained 77% of the time during the year-end rally period, according to data from Sundial Capital Research. The average gain in this nine-day trading period tallied 2.66%.</p>\n<p>Separately, Oppenheimer chief investment strategistJohn Stoltzfusdisclosedthe most bullish price target on the S&P 500, forecasting a 14% climb to 5,330 by the end of 2022. The 38-year Wall Street veteran’s estimate beats even the most optimistic of his peers, BMO Capital Markets’s Brian Belski, who projected S&P 500 5,300.</p>\n<p>Meanwile, Pfizer (PFE)received authorization from the U.S. Food and Drug Administration for its at-home COVID-19 pill following clinical trial data that showed the treatment was 90% effective at preventing hospitalizations and deaths in high-risk patients. Shares of Pfizer gained more than 2% in Wednesday's session following the news and closed up 1.02% at $59.55 a piece.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199712599","content_text":"All three major averages were up Thursday morning, building on back-to-back sessions of gains as fears the Omicron variant would derail economic growth cooled among investors who sold-off risky assets at the start of the week on reports of swelling case numbers.\nThe Nasdaq briefly jumped 180 points, while the Dow Industrial Average and S&P 500 also edged higher.\nInvestors are weighing a trove of economic releases this morning. The Labor Department reported that initial jobless claims totaled 205,000, sustaining a downward trend from the highs of their pandemic peak and reflecting labor market tightness brought on by a demand for workers heading into the new year. The latest print brings the four-week moving average for new claims to its lowest in 52 years, ticking up by 2,750 week-over-week to reach 206,250.\nU.S. durable goods orders rose by 2.5% in November, up from the prior month, boosted by a sharp rise in aircraft orders.\nMeanwhile, U.S. consumer prices accelerated at the fastest pace in nearly four decades as shoppers confront rising inflation levels ahead of the holidays.\nIn Wednesday's trading session, investors weighed an upbeat print on consumer confidence levels and the release of an upwardly revised estimate for domestic GDP, placing all three major averages in the green after a mixed open.\nThe Conference Board reported consumer confidence increased by a greater-than-expected margin in December,with the headline index at 115.8 during the month and higher than Bloomberg’s consensus estimates of 111.0. In November, the index had a reading of 111.9, revised from an initial report of 109.5. Meanwhile, the nation’s gross domestic product grew at an annual rate of 2.3% in the third quarter in the final estimate from the Bureau of Economic Analysis after the initial report of 2.1%.\n“We’ve been saying that this is definitely a buy the dip sort of market because we expect more earnings upgrades to come,” Anik Sen, PineBridge Investments global head of equities told Yahoo Finance Live. “We think that the real debate should be about the length and strength of the economic cycle ahead.”\nThe clock is also ticking on ayear-end Santa Claus Rally— one in which stocks climb higher in the final seven trading sessions of a year, plus the first two trading days of the new year. Starting tomorrow, traders will see whether 92 years of data uphold.\nFor reasons unclear, over the past 92 years, the S&P 500 gained 77% of the time during the year-end rally period, according to data from Sundial Capital Research. The average gain in this nine-day trading period tallied 2.66%.\nSeparately, Oppenheimer chief investment strategistJohn Stoltzfusdisclosedthe most bullish price target on the S&P 500, forecasting a 14% climb to 5,330 by the end of 2022. The 38-year Wall Street veteran’s estimate beats even the most optimistic of his peers, BMO Capital Markets’s Brian Belski, who projected S&P 500 5,300.\nMeanwile, Pfizer (PFE)received authorization from the U.S. Food and Drug Administration for its at-home COVID-19 pill following clinical trial data that showed the treatment was 90% effective at preventing hospitalizations and deaths in high-risk patients. Shares of Pfizer gained more than 2% in Wednesday's session following the news and closed up 1.02% at $59.55 a piece.","news_type":1},"isVote":1,"tweetType":1,"viewCount":800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690152971,"gmtCreate":1639648896720,"gmtModify":1639648910879,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690152971","repostId":"607301269","repostType":1,"repost":{"id":607301269,"gmtCreate":1639483841813,"gmtModify":1639548621206,"author":{"id":"3558937605407666","authorId":"3558937605407666","name":"46d9935c","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"2021年迄今录得机构净流入最高的20只股票回报率为32%","htmlText":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。<a target=\"_blank\" href=\"https://laohu8.com/S/D05.SI\">$星展集团控股(D05.SI)$<</a>","listText":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。<a target=\"_blank\" href=\"https://laohu8.com/S/D05.SI\">$星展集团控股(D05.SI)$<</a>","text":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。$星展集团控股(D05.SI)$<","images":[{"img":"https://static.tigerbbs.com/3a5aa837cdedb0dc52e1e45932e716e7","width":"688","height":"486"},{"img":"https://static.tigerbbs.com/e9724155d0def0ecd2771be6d26cc595","width":"688","height":"605"},{"img":"https://static.tigerbbs.com/c2a7b421a702a2d30d42bf04035cf1f9","width":"688","height":"405"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607301269","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843011905,"gmtCreate":1635781895489,"gmtModify":1635781895489,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843011905","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":641,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843019521,"gmtCreate":1635781837737,"gmtModify":1635781837737,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843019521","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698952783,"gmtCreate":1640286687678,"gmtModify":1640286687754,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698952783","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p>\n<p>The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p>\n<p>As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p>\n<p>The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p>\n<p>Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p>\n<p>The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p>\n<p>The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p>\n<p>Some experts question whether there will be much of a role for the Merck drug in the U.S.</p>\n<p>“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p>\n<p>For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p>\n<p>The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p>\n<p>Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p>\n<p>The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p>\n<p>Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:31 GMT+8 <a href=https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/><strong>SeattleTimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug ...</p>\n\n<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRK":"默沙东"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952835,"gmtCreate":1640286465896,"gmtModify":1640286465896,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952835","repostId":"1199712599","repostType":4,"isVote":1,"tweetType":1,"viewCount":800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952511,"gmtCreate":1640286571653,"gmtModify":1640286571653,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Go9oooooood","listText":"Go9oooooood","text":"Go9oooooood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952511","repostId":"1152565085","repostType":4,"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698952698,"gmtCreate":1640286479224,"gmtModify":1640286479327,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698952698","repostId":"1122468807","repostType":4,"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690152971,"gmtCreate":1639648896720,"gmtModify":1639648910879,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690152971","repostId":"607301269","repostType":1,"repost":{"id":607301269,"gmtCreate":1639483841813,"gmtModify":1639548621206,"author":{"id":"3558937605407666","authorId":"3558937605407666","name":"46d9935c","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"2021年迄今录得机构净流入最高的20只股票回报率为32%","htmlText":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。<a target=\"_blank\" href=\"https://laohu8.com/S/D05.SI\">$星展集团控股(D05.SI)$<</a>","listText":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。<a target=\"_blank\" href=\"https://laohu8.com/S/D05.SI\">$星展集团控股(D05.SI)$<</a>","text":"本文章是新加坡交易所官方文章关于机构投资新加坡蓝筹股[财迷] 2021年截至12月3日，录得机构净流入最高的20只股票的净买入总计为28亿新元，过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。 在这20只股票28亿新元的净买入中，超过4亿新元是自9月30日以来录得，其中，有11只股票在过去九周内录得机构净流入，大华银行、星展银行和永科领涨其他股票。12月3日，永科创下5.29新元的新高，这使得其2021年截至12月3日的总回报率达到55%。 这20只股票涵盖过去48周内全球股票行业中表现较为强劲的部分行业，如银行、工业类REIT、农业和半导体，此外，还包括报业控股、胜科工业和凯德投资公司等一年来持续进行战略重组的股票。 2020年底收于近2,850点后，海峡时报指数全年呈上升趋势，在11月26日出现的Omicron变异毒株给全球股票基准带来冲击之前，于11月9日创下超过3,250的高点，这使得海峡时报指数达到目前接近3,100点的水平。海指今年录得13%的总回报率，而富时亚太指数的总回报率则为3%。2021年截至12月3日，超过300只新加坡上市股票录得机构净流入。过去48周内录得机构净买入最高的20只股票占这300只股票机构净流入总额的75%，星展银行、大华银行和报业控股领涨这20只股票。上述20只股票在过去48周内的平均总回报率为32%，其中，有17只股票超过海峡时报指数13%的总回报率，19只股票超过富时亚太指数3%的总回报率。这20只股票及它们在2021年截至12月3日的机构净流入（自9月30日以来的机构净流入/流出除外）如下表所示。$星展集团控股(D05.SI)$<","images":[{"img":"https://static.tigerbbs.com/3a5aa837cdedb0dc52e1e45932e716e7","width":"688","height":"486"},{"img":"https://static.tigerbbs.com/e9724155d0def0ecd2771be6d26cc595","width":"688","height":"605"},{"img":"https://static.tigerbbs.com/c2a7b421a702a2d30d42bf04035cf1f9","width":"688","height":"405"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607301269","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843011905,"gmtCreate":1635781895489,"gmtModify":1635781895489,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843011905","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":641,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843019521,"gmtCreate":1635781837737,"gmtModify":1635781837737,"author":{"id":"3562111968746343","authorId":"3562111968746343","name":"Yue7","avatar":"https://static.tigerbbs.com/eb04a4755e1e2aabf66975d89c053a2e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Share","listText":"Share","text":"Share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843019521","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap here to play the Halloween game, and you stand a chance to win various rewards! </a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
